Rejected at 12:59 a.m. Jul, 24, 2025 ] by yelbardisi
Author: anknovice
Related Note: 1481330642022
Rationale for change

changed description of JAK2 as a tyrosine kinase to read "non-receptor tyrosine kinase". this wording is more clear and consistent with other cards too.
Source: Other - common knowledge

Rejection reason

Please resubmit with an acceptable source. Please review suggestion guidelines, specifically rule #1: https://community.ankihub.net/t/anking-step-deck-submission-guidelines/166504

Extra Extra
Text
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo
Empty field
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Step1_v12::#UWorld::Step::15323 #AK_Step1_v12::^Systems::HemeOnc::WBC #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::03_Myeloproliferative_Disorders::03_Essential_Thrombocythemia #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::31_Polycythemia::*Polycythemia_Vera #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::29_Myeloproliferative_neoplasms::01_Polycythemia_vera #AK_Step1_v12::#SketchyPath::10_Myeloid_&_Lymphoid::01_Myeloid_Disorders::03_Polycythemia #AK_Step1_v12::#UWorld::Step::8591 #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::05_Bone_Marrow_Failure::01_Bone_Marrow_Failure_DDx #AK_Step1_v12::^Other::^EXPN::Boards&Beyond #AK_Step1_v12::#Pathoma::06_WBC::04_Myeloproliferative #AK_Step1_v12::#UWorld::COMLEX::25437 #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::10_Plasma_Cell_Dyscrasias_&_Myeloproliferative_Disease::03_Polycythemia_Vera_&_Essential_Thrombocythemia #AK_Step1_v12::#SketchyPath::10_Myeloid_&_Lymphoid::01_Myeloid_Disorders::01_Myeloproliferative_Neoplasms_&_Myelodysplastic_Syndromes #AK_Step1_v12::^Other::^EXPN::Uworld #AK_Step1_v12::#OME::04_Organ_Systems::05_Hematology_Oncology::04_Proliferation::02_Myeloproliferation #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::03_White_Cells::02_Myeloproliferative_Disorders #AK_Step1_v12::#B&B::09_Endocrinology::05_Other::06_Signaling_Pathways #AK_Other::#AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Hematology_&_Oncology::Pathoma_WBC #AK_Step1_v12::#UWorld::COMLEX::26236 #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::03_Myeloproliferative_Disorders::02_Polycythemia_Vera #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::03_Myeloproliferative_Disorders::01_Myeloproliferative_Disorders_Overview #AK_Step1_v12::#B&B::12_Hematology::03_White_Blood_Cells::07_Myeloproliferative_Disorders #AK_Step1_v12::#AMBOSS::CnaqvO #AK_Step1_v12::^Other::^EXPN::BGedit #AK_Step1_v12::#OME::Clinical::04_Organ_Systems::05_Hematology_Oncology::04_Proliferation::02_Myeloproliferation #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::10_Plasma_Cell_Dyscrasias_&_Myeloproliferative_Disease::04_Myelofibrosis_and_Myelodysplastic_Syndromes #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::04_Oncology::02_Chronic_Leukemias_SOAP #AK_Step1_v12::#Physeo::11_Pathology::10_HemeOnc_Pathology::14_Myeloproliferative_Disorders #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::29_Myeloproliferative_neoplasms::*Chronic_Myeloproliferative_Disorders::Basics